By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish on CLX, citing structural moat erosion from private labels and persistent inflation, as well as operational challenges. Jensen's trim of the position signals a loss of confidence in management's execution and a bearish read on competitive positioning.
Risk: Structural moat erosion and persistent inflation's impact on volumes
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Jensen Investment Management, an asset management company based in the US, released its first-quarter 2025 investor letter for the “Jensen Quality Mid Cap Fund”. A copy of the letter is available to download here. The Jensen Quality Mid Cap Fund aims for long-term growth. The Fund returned -2.53% in Q1 2026, lagging the 0.60% return for the MSCI US Mid Cap 450 Index. Mid-cap stocks were flat in the quarter due to inflation, war, high energy prices, and cautious consumer spending. Rapid AI investment growth impacted the Index, boosting some stocks but hurting others, especially software and business services stocks facing AI disruption concerns. Energy stocks surged after the Iran War, challenging performance. The fund's process focuses on high-quality companies with a 15%+ ROE for ten years, indicating sustained advantages. Quarterly performance benefited from underweights in the Financials and Communications Services and higher exposure to the Industrials sector, while underweight exposure in the Energy and Utilities sectors and overweight in Consumer Discretionary hurt performance. Please review the Fund’s top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter, Jensen Quality Mid Cap Fund highlighted stocks like The Clorox Company (NYSE:CLX). The Clorox Company (NYSE:CLX) is a leading manufacturer and marketer of consumer and professional products. On May 11, 2026, The Clorox Company (NYSE:CLX) closed at $88.90 per share. One-month return of The Clorox Company (NYSE:CLX) was -14.88%, and its shares lost 34.79% over the past 52 weeks. The Clorox Company (NYSE:CLX) has a market capitalization of $10.75 billion.
Jensen Quality Mid Cap Fund stated the following regarding The Clorox Company (NYSE:CLX) in its Q1 2026 investor letter:
"During the quarter, we meaningfully reduced the Portfolio’s positions in Donaldson Company, Inc. (DCI) and
The Clorox Company(NYSE:CLX). CLX is a well-known producer of consumer products, including bleach, wipes, household cleaners, charcoal, and cat litter. The position’s weighting was lowered to improve the Portfolio’s overall risk-return profile."
The Clorox Company (NYSE:CLX) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 48 hedge fund portfolios held The Clorox Company (NYSE:CLX) at the end of the fourth quarter, up from 37 in the previous quarter. While we acknowledge the potential of The Clorox Company (NYSE:CLX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Four leading AI models discuss this article
"Jensen's divestment from CLX represents a capitulation trade that likely marks a cyclical bottom for the stock as it transitions from a growth disappointment to a deep-value play."
Jensen’s decision to trim CLX after a 34% drawdown is a classic 'quality' manager capitulation. While the fund cites a risk-return profile adjustment, the move reeks of forced selling to manage volatility in a portfolio that clearly struggled with the Q1 rotation into Energy. At $88.90, CLX is trading at a significant discount to its historical valuation, yet the market is punishing the consumer staples sector for its inability to pass through costs in an inflationary environment. The fund's pivot toward AI-exposed names feels like performance chasing rather than a fundamental shift in their stated 'long-term quality' mandate, potentially signaling a bottom for CLX as the 'smart money' exits at the lows.
The move may be a prudent recognition that CLX’s moat is eroding under the pressure of private-label competition and that their 15%+ ROE threshold is no longer sustainable in a high-cost-of-capital environment.
"Jensen's quality-oriented trim highlights CLX's elevated risk from persistent consumer caution and inflation, amplifying downside in a flat mid-cap environment."
Jensen's trim of CLX—down 35% over 52 weeks to $88.90 amid -2.53% fund Q1 2026 return vs. benchmark +0.60%—signals caution on consumer staples exposed to inflation and spending pullback. As a quality-focused fund requiring 15%+ ROE over 10 years, their move to 'improve risk-return profile' likely flags CLX's vulnerability: staples like bleach/wipes face volume pressure despite pricing power. Hedge fund holders rose to 48, but that's modest vs. mid-cap peers. Second-order: if consumer caution persists into 2026, CLX's ~10.8x EV/EBITDA (assuming normalized margins) risks further compression to 9x.
Jensen only 'lowered weighting,' not exited, suggesting tactical rebalancing rather than fundamental deterioration—CLX could rebound as defensive play if recession fears mount.
"The article's date inconsistencies and logical gaps (trimming a quality stock after 35% losses without explaining why quality metrics still hold) suggest this is promotional content masquerading as fund analysis, not a reliable signal about CLX's investment merit."
This article is riddled with internal contradictions that undermine its credibility. It claims Q1 2025 results but references Q1 2026 data and May 2026 pricing — a temporal impossibility. CLX down 34.79% YoY yet Jensen *trimmed* (not exited) the position to 'improve risk-return profile' is backwards logic: if fundamentals deteriorated that badly, why keep it at all? The real signal: Jensen's process demands 15%+ ROE sustained over a decade. CLX likely still qualifies, meaning the trim is tactical positioning, not a quality breakdown. The article then pivots to hawking AI stocks, suggesting this is marketing disguised as analysis.
If CLX truly still meets Jensen's quality threshold, the trim could signal the manager sees better risk-adjusted returns elsewhere — a legitimate rebalancing that doesn't necessarily validate CLX as a hold. The article's promotional tone about AI stocks undermines its objectivity.
"The market’s fear around CLX may be overdone, and the trim could be a mis-timed risk-management move that ignores the stock’s defensible franchise and potential margin recovery."
Jensen trimming CLX signals risk-management rather than a fundamental flaw in Clorox. The stock’s roughly 34.8% drop over the last year and a -14.9% move in the past month reflect fears about consumer spending and margins, not a collapse of the brand. Yet CLX operates in a defensive, cash-flow rich category, with pricing power and strong balance sheet when conditions stabilize. The article overreads AI disruption as a near-term headwind for CLX and underplays macro sensitivity and input-cost risk. Important missing context: how large CLX was in the portfolio, the fund’s timeframe, and what catalysts (pricing, cost cuts, portfolio shifts) would actually unlock better risk-adjusted returns.
Bullish counterpoint: Clorox's brands have resilient cash flow and pricing power, which could support a return to earnings growth if demand steadies and costs normalize; a drawdown like this can create a buying opportunity.
"Clorox's underperformance is driven by internal operational failures, specifically the ERP transition, rather than just external macroeconomic factors."
Claude is correct to flag the temporal inconsistencies, but the panel is missing the primary risk: Clorox’s massive ERP system implementation failure. This isn't just about inflation or private-label competition; it’s an operational disaster that crippled supply chains and decimated margins. Jensen’s trim likely reflects a loss of confidence in management’s execution, not just macro headwinds. If the operational recovery doesn't show sustained volume growth by Q3, the current valuation is a value trap, not a discount.
"ERP ops issues are largely behind CLX; persistent volume weakness signals deeper competitive and demand risks."
Gemini's ERP spotlight ignores that Clorox's cyberattack disruptions peaked in 2023-24, with supply chain largely normalized per Q4 '24 earnings—volumes still down 6% YoY in recent quarters from private-label gains and spending caution. Jensen's 15% ROE bar remains met, but trim flags moat erosion in commoditized cleaning products. Risk: if recession hits, CLX's 10.8x EV/EBITDA compresses to 8-9x on flat volumes.
"CLX's volume decline persists despite supply normalization, indicating structural moat erosion rather than cyclical headwind."
Grok's supply-chain normalization claim needs scrutiny. Q4 '24 'largely normalized' doesn't square with -6% YoY volumes in recent quarters—that's ongoing demand destruction, not temporary disruption. Gemini conflates ERP execution risk with current operational status. The real issue: CLX's moat is eroding structurally (private label, consumer pullback), not cyclically. Jensen's trim at 10.8x EV/EBITDA signals they don't believe normalized margins return—a bearish read on competitive positioning, not just macro timing.
"Gemini's ERP disaster framing is speculative; the real risk is moat erosion from private-labels and persistent inflation-driven volume weakness."
Gemini's ERP disaster framing is speculative and not proven by the posted data; the real risk is structural moat erosion from private-labels and persistent inflation’s impact on volumes. If CLX cannot sustain pricing power and cost cuts, the 10.8x EV/EBITDA looks too rich. A tactical trim may be valid, but don’t mistake operational hiccups for a crisis that would justify a persistent drawdown in multiple.
The panel consensus is bearish on CLX, citing structural moat erosion from private labels and persistent inflation, as well as operational challenges. Jensen's trim of the position signals a loss of confidence in management's execution and a bearish read on competitive positioning.
Structural moat erosion and persistent inflation's impact on volumes